【IHH 5225 交流专区】综合保健控股

icy97

Type	Announcement
Subject	OTHERS
Description	INTERNAL REORGANISATION OF IHH HEALTHCARE BERHAD’S GROUP STRUCTURE
Pursuant to Paragraph 9.19(5) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors of IHH Healthcare Berhad (“IHH” or “the Company”) is pleased to announce that Acibadem Poliklinikleri A.S. (“Acibadem Poliklinikleri”) and Konur Saglik Hizmetleri A.S. (“Konur Saglik”), indirect subsidiaries of the Company, had merged on 30 September 2014 (“Internal Reorganisation”). Following the Internal Reorganisation, all assets and liabilities of Konur Saglik had been transferred to Acıbadem Poliklinikleri and Konur Saglik was subsequently dissolved. Prior to the Internal Reorganisation, Konur Saglik was a wholly-owned direct subsidiary of Acıbadem Poliklinikleri. The Internal Reorganisation was undertaken in order to streamline the Acibadem group structure and management. The Internal Reorganisation will not have any effect on IHH’s issued and paid-up share capital and substantial shareholders’ shareholdings. There shall be no material effect on the Group’s earnings and net assets for the financial year ending 31 December 2014. None of the directors and major shareholders of IHH and persons connected to them has any interest, direct or indirect, in the Internal Reorganisation.

icy97

Type	Announcement
Subject	OTHERS
Description	INCORPORATION OF SUBSIDIARY – PARKWAY CHINA HOLDING CO. PTE. LTD.
Pursuant to Paragraph 9.19(23) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors of IHH Healthcare Berhad (“IHH” or “the Company”) wishes to announce that Parkway Group Healthcare Pte. Ltd., an indirect wholly-owned subsidiary of IHH, had on 13 October 2014, incorporated a foreign wholly-owned subsidiary named Parkway China Holding Co. Pte. Ltd. (“Parkway China”) in Singapore with paid-up capital of RMB6,165,000 (equivalent to RM3,282,2461) The intended principal activity of Parkway China is investment holding. The incorporation of Parkway China will not have any effect on IHH’s issued and paid-up share capital and substantial shareholders’ shareholdings. There shall be no material effect on the Group’s earnings and net assets for the current financial year ending 31 December 2014. None of the directors and/or substantial shareholders or persons connected to them, have any interest, direct or indirect in the above establishment.

icy97

券商買進心頭好．新增病床加強獲利 綜合保健控股評級上修

財經股市27 Oct 2014 22:00

券商 ：艾芬黃氏資本研究
目標價：5.50令吉

綜合保健控股（IHH，5225，主要板貿服）旗下持股的醫院計劃新增病床，以拓展大馬和土耳其業務，預計這有助改善公司賺幅和經營杠桿，同時上修目標價和投資評級，從“減持”至“增持”。

大馬百匯（Parkway）將于明年在亞庇和美迪尼開設兩家鷹閣（Gleneagles）醫院，分別設有250張和150張病床。

坐落在吉隆坡的鷹閣醫院新增額外100張病床工程料將在年底完成。

總計，大馬百匯明年底的病床數量將上漲25%。

土耳其Acibadem醫療公司放眼于明年開設2家新醫院，並計劃在2年內為現有3家醫院新增額外病床，病床數量料在明年底可增32%。

我們認為綜合保健控股一直以來都能順利執行擴展計劃，並改善收入和病人數量，相信更多的病床能助提高該公司的利息、稅務、折舊與攤銷前盈利（EBITDA）賺幅，我們因此調高2014至2016財年收益預測介于9%至21%。

綜合保健控股27日（週一）遊走介于4.95至4.99令吉之間，閉市收報4.97令吉，微跌1仙，全日交易量702萬6100股。【中国报财经】

icy97

Type	Announcement
Subject	OTHERS
Description	INTERNAL REORGANISATION OF THE IHH GROUP STRUCTURE
Pursuant to Paragraph 9.19(5) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad and as part of the internal reorganisation of the IHH Group structure, the Board of Directors of IHH Healthcare Berhad (“IHH” or “the Company”) is pleased to announce that Parkway China Holding Co Pte Ltd (“Parkway China”), an indirect wholly-owned subsidiary of IHH, has on 30 October 2014 acquired 2 shares representing 100% equity interest in M&P Investments Pte Ltd (“M&P”), an indirect wholly-owned subsidiary of IHH, for a consideration of S$2.00 (equivalent to RM5.151), from Parkway Holdings Limited, an indirect wholly-owned subsidiary of IHH (“Internal Reorganisation”). Following the Internal Reorganisation, M&P has become a direct wholly-owned subsidiary of Parkway China. The Internal Reorganisation will not have any effect on IHH’s issued and paid-up share capital and substantial shareholders’ shareholdings. There shall be no effect on the Group’s earnings and net assets for the financial year ending 31 December 2014. None of the directors and major shareholders of IHH and persons connected to them has any interest, direct or indirect, in the Internal Reorganisation. _________________________ 1 Based on the exchange rate of RM1.00: S$0.3887 on 30 October 2014 as set out in the Bank Negara website, subject to rounding

Type	Announcement
Subject	OTHERS
Description	INTERNAL REORGANISATION OF THE IHH GROUP STRUCTURE
Pursuant to Paragraph 9.19(5) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad and as part of the internal reorganisation of the IHH Group structure, the Board of Directors of IHH Healthcare Berhad (“IHH” or “the Company”) is pleased to announce that Parkway China Holding Co Pte Ltd (“Parkway China”), an indirect wholly-owned subsidiary of IHH, has on 31 October 2014 subscribed for 8,910 shares representing 99% equity interest therein in Medical Resources International Pte Ltd (“MRI”), an indirect wholly-owned subsidiary of IHH, at the subscription price of RMB10 (equivalent to RM5.371) (“Internal Reorganisation”).  The remaining 90 shares representing 1% equity interest in MRI is held by Parkway Group Healthcare Pte Ltd, an indirect wholly-owned subsidiary of IHH. The Internal Reorganisation will not have any effect on IHH’s issued and paid-up share capital and substantial shareholders’ shareholdings. There shall be no effect on the Group’s earnings and net assets for the financial year ending 31 December 2014. None of the directors and major shareholders of IHH and persons connected to them has any interest, direct or indirect, in the Internal Reorganisation. _______________________________ 1 Based on the exchange rate of RM1.00:RMB1.8609 on 31 October 2014 as set out in the Bank Negara website, subject to rounding

icy97

Type	Announcement
Subject	OTHERS
Description	IHH HEALTHCARE BERHAD (“IHH” OR THE “COMPANY”) INTERNAL REORGANISATION OF IHH’S GROUP STRUCTURE
Pursuant to Paragraph 9.19(5) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad and as part of the internal reorganisation of IHH Group structure, the Board of Directors of IHH is pleased to announce that Acibadem Labmed Saglik Hizmetleri ve Ticaret A.S. (“Acibadem Labmed”), a direct subsidiary of Acibadem Saglik Hizmetleri ve Ticaret AS. (“ASH”), which in turn is an indirect subsidiary of IHH, had on 20 November 2014 acquired 3,400,000 shares representing 100% equity interest in Blab Laboratuvar Hizmetleri A.S. (“Blab Laboratuvar”), from ASH for a total consideration of TL3,400,000 (equivalent to RM5,114,620)1 (“Internal Reorganisation”). Following the Internal Reorganisation, Blab Laboratuvar became a direct wholly-owned subsidiary of Acibadem Labmed. The purchase consideration is determined based on the nominal value of the shares in Blab Laboratuvar. The Internal Reorganisation will not have any effect on IHH’s issued and paid-up share capital and substantial shareholders’ shareholdings. There shall be no material effect on the Group’s earnings and net assets for the financial year ending 31 December 2014. Save as disclosed below, none of the directors and major shareholders of IHH and persons connected to them has any interest, direct or indirect, in the Internal Reorganisation: (a)     Mr. Mehmet Ali Aydinlar (“Mr. Aydinlar”) is a Director and shareholder of IHH and a Director of ASH, Acibadem Labmed and Blab Laboratuvar. He is holding one (1) share, representing 0.00001% of the total paid-up share capital in Acibadem Labmed and deemed interested in the Internal Reorganisation by virtue of his and his spouse shareholding therein; and (b)    Mrs. Hatice Seher Aydinlar, the spouse of Mr. Aydinlar, is a shareholder of IHH and a Director of ASH and Acibadem Labmed. She is holding one (1) share, representing 0.00001% of the total paid-up share capital in Acibadem Labmed and deemed interested in the Internal Reorganisation by virtue of her and her spouse shareholding therein. _____________________________________ 1 Based on the exchange rate of TL1.00 : RM1.5043 on 20 November 2014, subject to rounding

icy97

綜合保健控股 獲頒10.7億港醫院合約

財經股市24 Nov 2014 23:37
（吉隆坡24日訊）綜合保健控股（IHH，5225，主要板貿服）60%持有股權子公司GHK醫院私人有限公司，頒發總值24億8403萬港幣（約10億7084萬令吉）建築工程合約。

綜合保健控股向馬證交所報備，俊和-協興聯營公司將為GHK醫院設計，完成建設和維護位于香港仔南風徑的一間私人醫院。

根據報備文件，這份合約為期24個月，綜合保健控股將通過銀行貸款支付這個建築工程。

這份合約料不會影響綜合保健控股截至本財年12月底的收益。

NWS控股私人有限公司通過Media Year投資私人有限公司持有GHK醫院40%股權。【中国报财经】

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) RELATED PARTY TRANSACTIONS
Description	AWARD OF CONTRACT TO HIP HING-CHUN WO JOINT VENTURE (GH) BY GHK HOSPITAL LIMITED, AN INDIRECT 60% OWNED SUBSIDIARY OF IHH HEALTHCARE BERHAD
Pursuant to Paragraph 10.08(1) of the Bursa Malaysia Securities Berhad Main Market Listing Requirements (“MMLR”), the Board of Directors of IHH Healthcare Berhad (“IHH” or “the Company”) is pleased to announce that GHK Hospital Limited (“GHK”), an indirect 60% owned subsidiary of IHH, had awarded the main contract for superstructure works for GHK to Hip Hing-Chun Wo Joint Venture (GH) (“HHCW”) at a contract sum of HKD2,484,033,064.31 (equivalent to RM1,070,846,7821) (“Contract Sum”) upon the terms and conditions as set out in the Letter of Award dated 24 November 2014 (“Contract”). The superstructure works comprise the design, completion and maintenance of the main contract works for the development of a private hospital at Lot No. 458, Nam Fung Path, Aberdeen Inland, Hong Kong which was acquired via public tender on 13 March 2013. Further details of the Award of the Contract are as per file attached. http://www.bursamalaysia.com/market/listed-companies/company-announcements/1803537

Attachments Announcement - award of contract - final.pdf

icy97

醫院業務持續成長‧綜合保健第三季淨利揚25.5%

2014-11-26 11:17      
（吉隆坡25日訊）受醫院經營業務持續成長帶動，綜合保健（IHH,5225,主板貿服組）截至2014年9月30日止第三季淨利按年成長25.53%至1億4千690萬7千令吉，首9個月淨利則報5億1千506萬3千令吉，按年揚28.42%。

第三季營業額亦按年增加6.71%至17億8千394萬3千令吉，9個月營業額則走高8.65%至54億零660萬8千令吉。

該公司董事經理陳詩龍透過文告說，第三季業績表現趨強，主要歸功於住院病人人數增加和每病人營業額走高，新醫院開始運作亦帶來額外貢獻。

其中，子公司百匯班底（Parkway Pantai）醫院取得10%營業額成長和11%營運盈利增長，土耳其Acibadem控股營業額則小漲1%，營運盈利則跌2%，但主要歸咎於匯率差異。（星洲日報／財經）

SUMMARY OF KEY FINANCIAL INFORMATION 30/09/2014

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/09/2014	30/09/2013	30/09/2014	30/09/2013
		$$'000	$$'000	$$'000	$$'000

1	Revenue	1,783,943	1,671,718	5,406,608	4,976,318
2	Profit/(loss) before tax	205,806	169,638	792,177	591,367
3	Profit/(loss) for the period	158,770	127,542	608,142	474,867
4	Profit/(loss) attributable to ordinary equity holders of the parent	146,907	117,029	515,063	401,059
5	Basic earnings/(loss) per share (Subunit)	1.80	1.44	6.31	4.95
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.2700		2.2200

icy97

綜合保健購Radlink‧獅城競爭委員會存憂

2014-11-28 11:21      
（吉隆坡27日訊）新加坡競爭委員會（CCS）對綜合保健（IHH,5225,主板貿服組）收購Radlink亞洲私人有限公司計劃感到憂慮，將對此展開第二階段的評估。

將展開第二階段評估

新加坡競爭委員會發文告表示，綜合保健與Radlink亞洲的整合將顯著減少新加坡放射和圖像服務，以及放射性化學藥品（Radiopharmaceutical）供應商數量，因此需要作進一步競爭分析。

“因此，富斯保健（Fortis Healthcare）旗下診斷和分子成像單位收購案需要進入第二階段的評估。”

綜合保健是在今年9月宣佈，通過子公司Medi-Rad聯號有限公司以1億3千700萬新元（約3億4千653萬令吉），向新加坡富斯保健收購Radlink亞洲私人有限公司全數股權。

不過，綜合保健今日股價表現未受消息影響，全日上揚3仙，以最高的5令吉挂收。（星洲日報／財經）

icy97

注资GKS9 买疗养院 综合保健进军日本

财经新闻 财经  2014-11-30 11:18
（吉隆坡29日讯）综合保健控股（IHH，5225，主板贸服股）与日本Godo KaishaSamurai9（简称GKS9）签署默契伙伴合约（Silent Partnership Agreement），后者正式成为前者子公司。

综合保健控股子公司，Parkway Life产托旗下的Parkway LifeJapan4（简称PLJ4），昨天与GKS9签署上述合约。

根据合约，PLJ4将注资给GKS9，以35亿3500万日元（约1亿65万2055令吉）收购位于日本福冈的疗养院资产。

该收购案料可在末季完成，此后，GKS9将成为综合保健控股的子公司。【南洋网财经】

Type	Announcement
Subject	OTHERS
Description	CHANGE IN THE COMPOSITION OF THE GROUP
Pursuant to Paragraph 9.19(23) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors of IHH Healthcare Berhad (“IHH” or "the Company”) wishes to announce that Parkway Life Japan4 Pte Ltd (“TK Investor”), a special purpose entity of Parkway Life Real Estate Investment Trust (“Parkway Life REIT”), had on 28 November 2014 entered into a Tokumei Kumiaiagreement (or silent partnership agreement, the “TK Agreement”) with Godo Kaisha Samurai 9 (the “TK Operator”). Parkway Life REIT is an indirect 35.76% owned subsidiary of the Company. Pursuant to the TK Agreement, the TK Investor has injected funds into the TK Operator in relation to the acquisition of the following nursing home by the TK Operator (“Acquisition”) at a total purchase price of approximately ￥3,535,000,000 (approximately RM100,652,0551). The Acquisition is expected to complete in the fourth quarter of 2014. Property Location No. of Rooms Type of Property Habitation Jyosui Fukuoka City, Fukuoka, Japan 76 Nursing home Due to the nature of the arrangements under the TK Agreement, the TK Operator is under established terms that impose strict limitations on decision-making powers of the TK Operator’s management, resulting in the Group receiving the majority of the benefits relating to the TK Operator’s operations and net assets, being exposed to the majority of the risks incident to the TK Operator’s activities and retaining the majority of the residual or ownership risks related to the TK Operator and their assets. Consequently, the TK Operator is regarded as subsidiary of the Group pursuant to MFRS 10: Consolidated Financial Statements (“Change in Group Composition”). TK Operator is a private limited liability company incorporated in Japan on 24 September 2014 with an issued and paid-up share capital of ￥10,000. The principal activity of TK Operator includes investment/divestment, management and holding of real estate and real estate interest and other related real estate activities. The Change in Group Composition is not expected to have any material effect on the earnings per share, net assets or share capital of the Company and Group for the financial year ending 31 December 2014. None of the Directors and major shareholders of IHH and persons connected to them has any interest, direct or indirect, in the Change in Group Composition. 1 Based on the exchange rate of ￥100: RM2.8473 on 28 November 2014 as set out in the Bank Negara website.

icy97

淨利符預期‧綜合保健展望正面

2014-12-02 17:33      
（吉隆坡2日訊）市場正面看待綜合保健（IHH,5225,主板貿服組）未來的增長前景，惟該股估值偏高，分析員大致上都給予較保守的投資評級。
估值偏高

綜合保健2014財政年首9個月淨利按年成長28.42%至5億1千506萬3千令吉，普遍符合市場預期，唯獨落後MIDF研究的全年預測，僅佔後者預測的60%。該證券行將綜合保健的2014財政年淨利預測調低16%，全年淨利料成長28%，並在2015財政年進一步放慢至18%。

儘管如此，該集團旗下新加坡伊麗莎白諾維娜（Mount Elizabeth Novena）醫院在第三季營業額按年大漲72%，加上稅前息前折舊攤銷前獲利（EBITDA）受良好營運效率提振取得翻倍增長，是主要的淨利增長來源。大馬研究看好該醫院在來臨將交出更強勁的成長表現，助推動集團的收入表現。

綜合保健計劃在2018年前將床位從目前的6千張增加至9千張，為未來成張的動力來源。馬銀行研究認為，現有醫院以及新營運醫院的持續成張，有望抵銷未來新醫院所引發的初創成本。

此外，雖然該集團在新加坡的醫院面臨印尼醫療旅遊客戶人數減跌的現象，但來自其它海外市場的客戶卻有所增加，例如中東與緬甸市場。

另一方面，新幣的走強持續彌補土耳其里拉的疲弱走勢，而土耳其Acibadem控股的匯率風險也繼續受到美元計收入以及大量美元緩衝現金所對衝。

雖然大馬研究鍾愛綜合保健的擴充計劃、執行能力以及領域前景，惟該股估值已經處於偏高水平，本益比達43倍，高於同行對手。

興業研究也認為，綜合保健目前的股價基本上已反映出近期的各利好因素，因此股價成長空間有限。



（星洲日報／財經‧報道：孔令堯）


扩展马新土国医院 综合保健增床位利长线
财经新闻 财经  2014-12-05 11:02
http://www.nanyang.com/node/666853?tid=462

icy97

Type	Announcement
Subject	OTHERS
Description	INTERNAL REORGANISATION OF IHH HEALTHCARE BERHAD’S GROUP STRUCTURE
Pursuant to Paragraph 9.19(5) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors of IHH Healthcare Berhad ("IHH") is pleased to announce that Acibadem Labmed Sağlık Hizmetleri ve Ticaret A.S. (“Acibadem Labmed”), Blab Laboratuvar Hizmetleri A.S. (“Blab Laboratuvar”) and Histogenetics Acıbadem Laboratuvar Hizmetleri A.S. (“Histogenetics”), indirect subsidiaries of IHH, had merged on 11 December 2014 (“Internal Reorganisation”). Following the Internal Reorganisation, all assets and liabilities of Blab Laboratuvar and Histogenetics had been transferred to Acibadem Labmed and Blab Laboratuvar and Histogenetics were subsequently dissolved. Prior to the Internal Reorganisation, Blab Laboratuvar and Histogenetics were wholly-owned direct subsidiaries of Acibadem Labmed. The Internal Reorganisation was undertaken in order to streamline the Acibadem group structure and management. The Internal Reorganisation will not have any effect on IHH’s issued and paid-up share capital and substantial shareholders’ shareholdings. There shall be no material effect on the Group’s earnings and net assets for the financial year ending 31 December 2014. None of the directors and major shareholders of IHH and persons connected to them has any interest, direct or indirect, in the Internal Reorganisation.

icy97

股價反映成長前景‧綜合保健估值昂貴

2014-12-13 12:59      
（吉隆坡12日訊）綜合保健（IHH,5225,主板貿服組）潛存商機和競爭優勢備受看好，但分析員認為其未來增長前景已普遍反映在股價上，而股本回酬和週息率表現遜於同儕，整體估值相對昂貴。

達證券首次覆蓋報道綜合保健，認為其主要投資點為醫療保健服務需求提昇，預期老年人口增加將推動對醫療保健服務的需求，並將為公司帶來商機，而其關鍵市場現每千人床位數仍低於先進國的3張。

“此外，綜合保健在主要市場享有市場領導的優勢，現公司旗下38家醫院、醫療中心和診所共有超過6千800個床位，並計劃新增3千個床位，將總床位數提昇至9千800個。”

但達證券行雖青睞綜合保健管理能力、主要市場領先地位等優勢，卻憂慮公司恐面對平均3至5年的新醫院陣痛期，以及多國營運帶來的外匯浮動盈虧、監管制度、經濟、環境和競爭版圖變更等風險。

“更重要的是，在當前股價水平，綜合保健未來增長前景已普遍反映。”

達證券維持財測，2014和2015年預料淨利分別為7億1千150萬令吉和8億7千830萬令吉。

該股現以高於歷史平均企業價值倍數（EV/EBITDA）標準差（SD）1的水平進行交易，而其每股盈利增長雖與領域同儕相符，但股本回酬和週息率卻相對遜色，因此給予‘賣出’評級，目標家為4令吉65仙。”（星洲日報／財經‧報道：洪建文）

icy97

无意购达斯特医疗11.5% 综合保健否认进军泰国

财经新闻 财经  2015-01-06 03:03
（吉隆坡5日讯）综合保健控股（IHH，5225，主板贸服股）否认进军泰国市场，并表示现阶段无意收购曼谷达斯特医疗集团（Bangkok Dusit Medical）的11.5%股权。

《星报》引述消息报道指，综合保健控股正放眼收购曼谷达斯特医疗集团的11.5%股权，料通过发出新股及支付现金，来完成收购。

不过，该公司今日傍晚发出文告否认。

“在向董事和相关大股东求证后，我们澄清，公司没有收购曼谷达斯特医疗集团11.5%股权的意愿。”

曼谷达斯特医疗集团是泰国股票交易所内最大的医院营运者，旗下经营6家医院集团，共29家医院。

根据今日的闭市价18泰铢，曼谷达斯特医疗集团的11.5%股权，共值320.7亿泰铢（约34.5亿令吉）。

消息披露，综合保健控股一直有意进军泰国市场，而此收购可瞬间为公司提供市占率。

“若要全面献购则较耗时，且需符合更繁琐的条例。”

消息补充，综合保健控股的品牌辨识度高，首次公开募股（IPO）也很成功，而这项收购更有助于巩固其亚洲地位。

泰铢攀升有利业绩

MIDF研究分析员指出，综合保健控股收购曼谷达斯特医疗集团是合理的，因泰铢兑令吉在过去一年节节攀升。

“保健股不仅抗跌，净利也有保险客户所支撑，可说是增长型企业。”

另外，此收购也将成为综合保健控股未来的催化剂。

这是继收购了印度阿波罗医院的10.85%股权后，综合保健控股的第二项联号收购举动。【南洋网财经】

Type	Announcement
Subject	OTHERS
Description	RESPONSE TO ARTICLE ENTITLED “MALAYSIA’S IHH EYES THAI HOSPITAL OPERATOR”
We refer to the Article entitled “Malaysia’s IHH eyes Thai hospital operator” which was published on The Star dated 5 January 2015. IHH Healthcare Berhad (“IHH” or the “Company”), after having made due enquiries with all the Directors and the relevant major shareholders of the Company, wishes to announce that IHH has no intention to acquire an 11.5% associate stake in Bangkok Dusit Medical Services Pcl (BDMS) at this juncture. IHH will make appropriate announcement(s) to Bursa Malaysia Securities Berhad (“Bursa Securities”) in a timely manner in accordance with the Main Market Listing Requirements of Bursa Securities should there be any further development on the said matter.

icy97

icy97 发表于 24-7-2013 12:33 AM
综合保健精简营运 1291万卖鹰阁CRC

财经新闻 财经  2013-07-25 12:54

综合保健1401万 卖狮城鹰阁研究中心

财经新闻 财经  2015-01-10 02:59
（吉隆坡9日讯）综合保健控股（IHH，5225，主板贸服股）确定最终脱售价，以526万8000新元（约1401万3000令吉）脱售新加坡鹰阁临床研究中心（Gleneagles CRC）予Mitsui&Co私人有限公司和EPS机构。

综合保健控股向马交所报备，买卖双方已达成协议，独资间接子公司百汇控股将脱售鹰阁临床研究中心51%股权予买方。

根据合约，百汇控股也脱售鹰阁临床研究中心的4家独资子公司———中国、泰国澳洲鹰阁临床研究中心，以及鹰阁临床研究国际。

综合保健控股在去年7月与买方签署买卖合约，当时的脱售价为513万8000新元（约1291万令吉）。【南洋网财经】

Type	Announcement
Subject	OTHERS
Description	DISPOSAL OF SUBSIDIARIES – GLENEAGLES CRC PTE LTD & ITS SUBSIDIARIES
Further to the announcement made on 23 July 2013 in relation to the disposal of Gleneagles CRC Pte Ltd and its subsidiaries (the “Disposal”), the Board of Directors of IHH Healthcare Berhad wishes to announce that the final Price Consideration of the Disposal was fixed on 9 January 2015 atSGD5.268 million (equivalent to RM14.013 million1), based on the adjusted consideration mutually agreed between Parkway Holdings Limited, Mitsui & Co. Ltd and EPS Holdings Inc. (formerly known as EPS Corporation). 1 Based on the exchange rate of SGD1:RM2.66 on 9 January 2015 as set out in the Bank Negara website, subject to rounding

icy97

3医院营收扩大 综合保健看好保健旅游

财经新闻 财经  2015-01-21 09:15
（香港20日讯）综合保健控股（IHH，5225，主板贸服股）看好大马保健旅游增长潜力，放眼位于依斯干达Medini、曼绒，以及亚庇医院投入营运后，将可扩大国内业务的营业额贡献。

综合保健控股主席丹斯里阿布巴卡出席亚洲金融论坛，接受本报专访时说，大马目前在保健旅游领域的增长，与其他国家相比，仍稍显逊色，但相信国内的高素质医疗服务将可吸引外国人前来我国。

“曾有来自英国的顾客告诉我，大马的牙科医疗费用与英国相比便宜50%，他们大多前来大马居住两周，旅游兼接受牙科治疗服务，这显示大马市场仍拥有很大的商机。”

在新加坡业务中，保健旅游顾客达40%，但相较大马，保健旅游顾客仅达10%。

土国最出色

大马医药旅游数据显示，2013年以保健旅游为目的，前来大马的访客人数达70万人次，同年全球保健旅游的游客人数达1100万人。

他指出，保健旅游表现最好的是土耳其，许多欧洲国家，以及面临战乱的国家如利比亚，会在动荡时期暂时离开国内前往土耳其，在寻求医疗服务之时，也在该国旅游。

该公司通过持股60%的子公司Achibadam，涉猎土耳其医疗领域，后者在该国拥有17家医院。【南洋网财经】

icy97

传综合保健与TPG资本 欲购印度Global 医院

财经新闻 财经  2015-02-10 08:15
（吉隆坡9日讯）市场传出，综合保健控股（IHH，5225，主板贸服股）与国际私募投资公司TPG资本管理，皆有意收购印度Global医院的控制性股权。

路透社引述不具名消息，称两个机构入股Global医院的交易，总值高达3.5亿美元（约12.42亿令吉）。

Global医院是在去年宣布有意售股。

消息指出，创办人兼现任主席拉威德拉纳和私募基金Everstone资本，皆有意减持股权。

“（股权买卖的）洽谈已几近完成。这可能是足以控制医院业务的大部分股权，会在近期内完成洽商。”

Global医院发言人表示，公司正为脱售股权的事情，与“数人”会谈。他不愿进一步透露详情。

不愿置评

综合保健控股和TPG资本管理，亦不愿置评。

印度的保健领域公共开销，是全球偏低国家之一，所以分析员看好，私人保健业者的吸引力有增无减。

作为亚洲市值最高的业者，综合保健控股若成功收购Global医院股权，即象征集团进一步扩充印度保健市场。

集团目前持有印度最大私人连锁医院Apollo，股权近11%。

Global医院旗下有至少5栋医院，分布在孟买、清奈、班加罗尔和海德拉巴，提供逾2000个床位。【南洋网财经】

icy97

傳爭印度醫院‧綜合保健估值見頂

2015-02-10 16:57      
（吉隆坡10日訊）市場盛傳，綜合保健（IHH,5225,主板貿服組）與美國私募基金TPG資本（TPG Capital）競逐印度全球醫院集團（India Global Hospital）控制性股權，交易總值可能達到3億5千萬美元（約12億4千372萬令吉）。目前，印度全球醫院在孟買、真奈、邦加羅爾和海得拉巴營運8家醫院。

分析
大眾研究指出，雖然越來越多印度消費者願意為更好的醫療服務付錢，但在消息證實與綜合保健業績發佈前，他們無意調整目前的“中和”評級和4令吉50仙目標價。

該行補充，全球醫院集團2013年曾有10%股權易手，交易價值為30億印度盧比（約1億7千100萬令吉），以此推算，綜合保健和TPG可能洽購的股權達70%左右。

如果股權洽購屬實，綜合保健可望進一步擴增印度版圖。目前，該公司握有印度阿波羅醫院集團（Apollo Hospital Enterprise）的11%股權。

大眾研究表示，該公司2015年將增加更多病床與新醫院，相信營收成長持續強勁，惟其股價處2015財政年44倍本益比水平，估值不低，因此該行無意調整評級與目標價。

綜合保健預期將於本月26日（週四）公佈業績。（星洲日報／財經）

icy97

Type	Announcement
Subject	OTHERS
Description	ESTABLISHMENT OF A SUBSIDIARY – ACIBADEM INTERNATIONAL MEDICAL CENTER B.V.
Pursuant to Paragraph 9.19(23) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors of IHH Healthcare Berhad ("IHH") is pleased to announce that Acibadem Saglik Hizmetleri ve Ticaret A.S., an indirect subsidiary of IHH, had on 16 February 2015, established a foreign wholly-owned subsidiary named Acibadem International Medical Center B.V. (“AIMC”) in Rotterdam, Netherlands with an initial paid-up capital of EUR100,000 (equivalent to RM407,6201). The intended principal activity of AIMC is to establish and operate medical clinics, and to provide home treatment and care services. The establishment of AIMC will not have any effect on IHH’s issued and paid-up share capital and substantial shareholders’ shareholdings. There shall be no material effect on the Group’s earnings and net assets for the current financial year ending 31 December 2015. None of the directors and/or substantial shareholders or persons connected to them, have any interest, direct or indirect, in the above establishment.

icy97

重估和脱售收益带动 综合医保末季赚2.4亿

财经新闻 财经  2015-02-27 09:39
（吉隆坡26日讯）营业额走高，加上取得重估和脱售收益，综合保健控股（IHH，5225，主板贸服股）末季净利微扬4%，达2亿3922万8000令吉，宣布派息3仙。

截至12月31日末季，营业额则起8.8%，报19亿3741万1000令吉。

累计全年，净利增长19.5%，写7亿5429万1000令吉；营业额涨8.7%，报73亿4401万9000令吉。

根据文告，末季营业额走高归功于较多病人入院，以及新医院的开张。

该公司末季扣除利息、税务、折旧与摊销前盈利（EBITDA）扬30%，达5亿8750万令吉。

贡献源自较高的营业额，以及早前重估百汇生命房地产投资信托（PLife REIT），和脱售七家疗养院的收益。

综合保健控股的资产负债表稳健，去年的净负债从0.12倍，降至0.08倍；手握25亿令吉现金。

该公司相信，国内外有素质的私人保健需求依旧殷切。

随着不断扩大业务，2017年时，该公司将有能力供应9000张新床位，足以应付高涨的需求；而这也有助于推高营业额增长。

惟同时也预计会面临成本压力，因消费税即将开跑，且培训保健人员竞争加剧，导致工资上涨。

不过，综合保健控股将通过调整价格和改善营运效率减轻冲击。【南洋网财经】

SUMMARY OF KEY FINANCIAL INFORMATION 31/12/2014

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/12/2014	31/12/2013	31/12/2014	31/12/2013
		$$'000	$$'000	$$'000	$$'000

1	Revenue	1,937,411	1,780,133	7,344,019	6,756,451
2	Profit/(loss) before tax	428,999	290,195	1,221,176	881,562
3	Profit/(loss) for the period	335,142	258,992	943,284	733,859
4	Profit/(loss) attributable to ordinary equity holders of the parent	239,228	230,100	754,291	631,159
5	Basic earnings/(loss) per share (Subunit)	2.93	2.83	9.24	7.78
6	Proposed/Declared dividend per share (Subunit)	3.00	2.00	3.00	2.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.3800		2.2200

Type	Announcement
Subject	OTHERS
Description	FIRST & FINAL SINGLE TIER CASH DIVIDEND FOR FINANCIAL YEAR ENDED 31 DECEMBER 2014
Pursuant to Paragraph 9.19(2) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors is pleased to propose a first and final single tier cash dividend of 3 sen per ordinary share for the financial year ended 31 December 2014, subject to shareholders’ approval at the forthcoming Annual General Meeting. The book closure and the payment date in respect of the proposed dividend will be determined by the Board of Directors at a later date.

icy97

Type	Announcement
Subject	OTHERS
Description	REVALUATION OF INVESTMENT PROPERTIES
Pursuant to Paragraph 9.19(46) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, the Board of Directors of IHH Healthcare Berhad  wishes to announce that the Group had undertaken the revaluation exercise of its Investment Properties. Please refer to the attachment for full announcement. http://www.bursamalaysia.com/market/listed-companies/company-announcements/1886477

Attachments IHH_Announcement_Valuation of investment properties_26022015.pdf